Factor Xa Inhibitor Plasma Concentrations and Clinical Outcomes in Patients Weighing ≤50 kg—Experience from Four UK Centers

Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation

(2021) Karlyn A. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD‐VTE

(2021) Jeffrey I. Weitz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Low Body Weight

(2019) So-Ryoung Lee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight

(2019) Stefan H. Hohnloser et al.   CIRCULATION

International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

(2018) Robert Gosselin et al.   THROMBOSIS AND HAEMOSTASIS

Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH

(2016) K. Martin et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE